Research on lung cancer and metabolomics, using mouse models.
The Sayin lab is positioned in the intersection between lung cancer therapeutics, cancer metabolism and redox biology. We are building a precision medicine platform combining the latest technologies in lung cancer research and metabolomics to establish an extensive translational lung cancer group at Sahlgrenska Center for Cancer Research.
Some of the aims of the lab are:
Identifying druggable targets in RAS and RAF driven cancers by combining a high-throughput screening platform using lentiviral-CRISPR/Cas9 with metabolomics and state-of- the- art genetically engineered mouse models of lung adenocarcinoma.
Developing patient-derived xenograft (PDX) models by transplanting fresh tumor pieces subcutaneously and orthotopically in humanized-immunocompromised mice. The humanized-PDX platform has the capacity to maintain patient-derived immune cells and will be used for both experimental studies and pre-clinical trials.
Identifying redox-metabolism related weaknesses in cancer cells, as well as analyzing the impact of genetic alterations in the redox network on tumor-associated immune cells and its effect on tumor initiation and progression, and immunotherapy.
The overarching objective of our research is to improve the quality of life and survival rates of cancer patients, guide personalized clinical trials, repurpose pre-existing drugs, and find novel combination therapies that can synergize with current standard-of-care therapies, including chemo- and immunotherapies.
Research tools and resources
Being a multifaceted lab, we use a wide range of cell- and molecular biology methods and reagents.
We use cellular and animal models. Some of these are cancer cell lines, reporter cell lines, biosensors, primary cells and qPCR, GC-MS, IP, WB, IF/IHC, HCS microscopy, and compound screening, among many others.
Our lab has developed lentiviral-CRISPR/Cas9 strategies to inactivate any gene-of-interest at tumor onset or later during tumor progression and metastasis.
We have set up a genome-wide CRISPR/Cas9 platform for identifying synthetic lethal targets or novel combination therapies for cancer.
Current group members
Volkan Sayin, PhD, Assistant Professor, Principal Investigator
Kristell Le Gal Beneroso, PhD, Postdoctoral Researcher, Lab Manager
Nadia Gul, PhD, Postdoctoral Researcher
Ahmed El Zowalaty, Postdoctoral Researcher
Ella Äng, MD, PhD candidate
Angana Patel, MSc, Research Assistant
Jozefina Dzanan, MSc, Research Assistant